Interferon regulatory factor 9 is an essential mediator of heart dysfunction and cell death following myocardial ischemia/reperfusion injury

详细信息    查看全文

• 作者：Yan Zhang ; Xiaoxiong Liu ; Zhi-Gang She ; Ding-Sheng Jiang…
• 关键词：IRF9 ; Ischemia–reperfusion injury ; Sirt1 ; P53
• 刊名：Basic Research in Cardiology
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：109
• 期：5
• 全文大小：5,804 KB
• 参考文献：1. Alcendor, RR, Kirshenbaum, LA, Imai, S, Vatner, SF, Sadoshima, J (2004) Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 95: pp. 971-980 CrossRef
  2. Blander, G, Guarente, L (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73: pp. 417-435 CrossRef
  3. Chen, K, Gao, L, Liu, Y, Zhang, Y, Jiang, DS, Wei, X, Zhu, XH, Zhang, R, Chen, Y, Yang, Q, Kioka, N, Zhang, XD, Li, H (2013) Vinexin-beta protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway. Basic Res Cardiol 108: pp. 338 CrossRef
  4. Cheng, HL, Mostoslavsky, R, Saito, S, Manis, JP, Gu, Y, Patel, P, Bronson, R, Appella, E, Alt, FW, Chua, KF (2003) Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 100: pp. 10794-10799 CrossRef
  5. Frangogiannis, NG, Smith, CW, Entman, ML (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53: pp. 31-47 CrossRef
  6. Frohlich, GM, Meier, P, White, SK, Yellon, DM, Hausenloy, DJ (2013) Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 34: pp. 1714-1722 CrossRef
  7. Hausenloy, DJ, Yellon, DM (2013) Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 123: pp. 92-100 CrossRef
  8. Heusch, G, Libby, P, Gersh, B, Yellon, D, Bohm, M, Lopaschuk, G, Opie, L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383: pp. 1933-1943 CrossRef
  9. Hofmann, U, Frantz, S (2013) How can we cure a heart “in flame- A translational view on inflammation in heart failure. Basic Res Cardiol 108: pp. 356 CrossRef
  10. Hsu, CP, Zhai, P, Yamamoto, T, Maejima, Y, Matsushima, S, Hariharan, N, Shao, D, Takagi, H, Oka, S, Sadoshima, J (2010) Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation 122: pp. 2170-2182 CrossRef
  11. Jenner, RG, Young, RA (2005) Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol 3: pp. 281-294 CrossRef
  12. Jiang, DS, Bian, ZY, Zhang, Y, Zhang, SM, Liu, Y, Zhang, R, Chen, Y, Yang, Q, Zhang, XD, Fan, GC, Li, H (2013) Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension 61: pp. 1193-1202 CrossRef
  13. Jiang, DS, Li, L, Huang, L, Gong, J, Xia, H, Liu, X, Wan, N, Wei, X, Zhu, X, Chen, Y, Chen, X, Zhang, XD, Li, H (2014) Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload. Hypertension 64: pp. 77-86 CrossRef
  14. Jiang, DS, Liu, Y, Zhou, H, Zhang, Y, Zhang, XD, Zhang, XF, Chen, K, Gao, L, Peng, J, Gong, H, Chen, Y, Yang, Q, Liu, PP, Fan, GC, Zou, Y, Li, H (2014) Interferon regulatory factor 7 functions as a novel negative regulator of pathological cardiac hypertrophy. Hypertension 63: pp. 713-722 CrossRef
  15. Jiang, DS, Luo, YX, Zhang, R, Zhang, XD, Chen, HZ, Zhang, Y, Chen, K, Zhang, SM, Fan, GC, Liu, PP, Liu, DP, Li, H (2014) Interferon regulatory factor 9 protects against cardiac hypertrophy by targeting myocardin. Hypertension 63: pp. 119-127
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1435-1803

文摘

This study aimed to investigate whether interferon regulatory factor 9 (IRF9) is involved in the pathogenesis of myocardial ischemia–reperfusion (I/R) injury and to explore the underlying molecular mechanisms of this process. Cell death plays a major role in myocardial I/R injury. We recently determined the importance of IRF9 in coordinating molecular events in response to hypertrophic stress in cardiomyocytes. However, the roles of IRF9 in lethal myocardial injury remain to be elucidated. The involvement of IRF9 was assessed via functional assays in a mouse myocardial I/R injury model by genetic knockout and cardiomyocyte-specific transgenic overexpression of IRF9, and its effects on cardiomyocyte apoptosis and inflammation were further studied in vivo and in vitro. IRF9 was upregulated in human ischemic heart tissue and mouse hearts after I/R injury. Ablation of IRF9 protected the heart against I/R-induced cardiomyocyte death, development of inflammation, and loss of heart function. In contrast, cardiomyocyte-specific transgenic overexpression of IRF9 aggravated myocardial reperfusion injury and inflammation. IRF9 negatively regulated the Sirt1-p53 axis under I/R conditions in vivo and in vitro. Downregulation of Sirt1 expression and its downstream apoptosis-related signaling cascade, which results from I/R, was ameliorated by loss of IRF9 and exacerbated by overexpression of IRF9. Cardiomyocyte-specific deletion of Sirt1 abolished the protective effect of IRF9 knockout against I/R injury, which further indicated that IRF9 mediated myocardial reperfusion injury by modulating the Sirt1-p53 axis. Thus, IRF9 may be a novel therapeutic target for the prevention of I/R injury resulting from revascularization therapy after acute myocardial infarction (MI).